FORTREA OPHTHALMOLOGY

Improving patient lives by advancing ocular therapies to market.

Deep clinical experience drives personalized ophthalmology solutions

Fortrea brings to the industry a 30-year CRO heritage, formerly as part of Covance and Labcorp Drug Development, including all of the ophthalmology experience gained during the 2017 acquisition of Chiltern. This allows us to offer diverse experience in ophthalmology across multiple indications, in both front and back-of-the-eye indications, as well as in rare ocular diseases, cell and gene therapies, pediatrics and ophthalmic devices and diagnostics. We partner with sponsors on trial designs emphasizing patient safety, quality data, and reducing the burden on all stakeholders, with a particular focus on patients, caregivers, and site relationships. In the past five years alone we have worked with sponsors on over 110 ophthalmology trials with sites spanning 45 countries

Extending your team's expertise though collaboration and providing strategic vision for your ophthalmic program

At Fortrea, we strive to be more than just a partner. We take a one-team approach to study design and expectation to reduce burden on patients, as well as investigator sites. We have deep scientific and regulatory expertise and insights that help provide flexible solutions for both large pharma companies and emerging and mid-size biotech companies. You can rely on us to extend your team by providing comprehensive support for clinical trials, including consultation, customized study monitoring, protocol writing, global logistics, specimen management, lab management and oversight, patient and site support services, regulatory support, and ocular-specific vendor contracting and management.

KEY TAKEAWAYS

114*

Patient-centric ophthalmology clinical trials with 1993 sites and 12,616 patients (68% posterior/32% anterior split)

21*

Ocular cell and gene therapy studies with 2,084 patients

36*

Rare ocular disease trials with 2,193 patients

* 5-year data from 2018-2022

Fortrea

Top Indications in Fortrea Ophthalmology Studies 2018-2022



Incorporating perspectives from across the industry

We are the sole CRO participating in the Ocular Diseases Forum, a therapeutic-specific section of The Forum for Collaborative Research established in 1997. Tanya Richardson, Fortrea's Executive Director for Ophthalmology, serves on the Steering Committee for this forum, known for its diverse stakeholder engagement, including academia, industry, patient representatives, payors and regulatory agencies. The forum collaborates closely with the FDA and EMA to advance regulatory science in treating inherited retinal diseases (IRDs) and macular degeneration. Additionally, we are the only CRO involved in The Vision Consortium at RARE-X, Industry Advisory Group, which fosters collaboration in rare genetic ocular disorders. We also participate in the Mary Tyler Moore Vision Initiative, a public-private consortium focused on diagnosing Diabetic Retinal Disease, developing new research endpoints and improving patient care.

Enhancing your drug development journey with tailored solutions and multiple data sources

Our science and data are always inspired by patients. Multiple differentiated data sources help establish a data and relationship-driven, realistic and deliverable strategy.

Fortrea has exclusive CRO access to Labcorp's diagnostic data, one of the largest sources of actual patient data in the world (30 billion test results and growing), to help identify patient clusters that meet inclusion and exclusion criteria.

Patient Intelligence Suite provides data from 135,000+ global "voice of the patient" surveys to provide unique, critical insights for improved protocol design and faster patient recruitment. This suite of technology-enabling tools is designed to increase drug development efficiency, reduce timelines, improve data quality, support study compliance and maximize product access.

Fortrea retains CRO exclusivity for a fixed time to Global Trial Source, a proprietary Labcorp database that provides access to the data of 150 million patients globally, plus insights from the Labcorp Central Lab data from over 50 percent of all trials globally. These data are used to identify realistic recruitment rates, startup timelines and high-performing sites and countries.

Furthermore, access to de-identified lab results and Patient Intelligence data helps pressure-test protocols and locate patients near proven, experienced investigator sites we are partnered with.

We also enable intelligent patient recruitment with advanced data and increase efficiencies through established relationships with a robust number of global sites.

Optimizing clinical trials with flexible testing and patient-centric solutions focused on the path to commercialization

At Fortrea, we are driven to deliver with urgency. Our extensive experience with regulatory and commercial guidance and in assisting small biotech and large pharma companies promotes goal achievement. We offer decentralized clinical trial approaches to mitigate delivery risks and provide full-service or functional service provider (FSP) models to help optimize delivery.

Our delivery capabilities are designed to match your preferences and the needs of your project and include comprehensive full-service solutions. Fortrea has the experience and understanding of how to operationalize ophthalmology studies and all of the related nuances, focusing on reducing site and patient burden.

Xcellerate® Suite allows us to not only track project data and milestones, but also allows for proactive management of your trials, helps identify and mitigate potential risks, accelerates patient recruitment, optimizes trial costs, ensures transparency and higher data quality and helps plan and manage trial execution for accuracy.

Fortrea's decentralized trial innovations help reduce patient burden and encourage patient participation and retention, while patient-centric trial design helps keep patients engaged throughout the trial process, leading to higher compliance rates and fewer trial dropouts.

LEARN MORE at fortrea.com

Fortrea